Clinicalstudy of low dose dexamethasone in preventing severe CRS after CD19 CAR-T therapy

VernacularTitle:小剂量地塞米松预防CD19 CAR-T细胞治疗后严重细胞因子释放综合征的临床研究
Author: Dan CHEN ¹ ; Rong HUANG ¹ ; Hao YAO ¹ ; Xiao WANG ¹
Author Information

1. Department of Hematology, the General Hospital of Western Theater Command, Chengdu 610083, China
Publication Type:Journal Article
Keywords: dexamethasone; CAR-T; CRS; ALL
From: Chinese Journal of Blood Transfusion 2021;34(12):1317-1320
CountryChina
Language:Chinese
Abstract: 【Objective】 To investigate the clinical application value of low dose dexamethasone in CRS prevention after CD19 CAR-T therapy. 【Methods】 67 cases of acute lymphoblastic leukemia(ALL) patients from January 2018 to March 2021 were selected as the research subjects. According to the admission time, patients were divided into dexamethasone prevention(DDD≤5 mg)group(n=36)and the control(n=31). The incidence of severe CRS and treatment outcome were compared. 【Results】 In the dexamethasone prevention group and the control, the incidence of severe CRS were 8.3%(3/36)vs 38.7%(12/31)(P<0.05), the number of CAR-T cells(cells/μL) was 329(83~371)vs 372(76~965)(P>0.05), the complete remission rate was 91.7%(33/36)vs 87.1%(27/31)(P>0.05), and the infection rate was 33.3%(12/36)vs 35.4%(11/31)(P>0.05). 【Conclusion】 The low dose dexamethasone as a prophylactic could significantly reduce the incidence of severe CRS, but had no influence on CAR-T cell proliferation and treatment outcome.